Pharmacokinetics of 250 μg, 375 μg and 500 μg roflumilast in children and adolescents with mild to moderate asthma and healthy adult subjects – an open, one-period, three parallel group design with repeated oral doses of once daily roflumilast for 14 days

Study identifier:BY217/CP-065

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting ClinicalTrialTransparency@AstraZeneca.com.

Medical condition

asthma

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Sex

All

Actual Enrollment

Study type

Interventional

Age

6 Years - 40 Years

Date

Study Start Date: 01 Jul 2005

Primary Completion Date: -

Study Completion Date: 01 Sept 2005

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2025 by Takeda

Collaborators

Inclusion and exclusion criteria

Location

Research Facility

United States

Arms	Assigned Interventions

Documents available

Download
CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com